AcuraStem

Executive Summary

AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases, including sporadic ALS and frontotemporal dementia (FTD). Leveraging its proprietary iNeuroRx® platform, the company uses patient-derived motor neurons to model disease pathology and screen for broadly-acting therapeutics. This approach enables the discovery of novel small molecules and biologics that target common mechanisms across patient populations, addressing a critical unmet need in diseases where sporadic cases predominate and genetic subtypes are diverse. By focusing on patient-relevant models, AcuraStem aims to improve translational success and develop treatments with higher efficacy and broader applicability. The company has built a robust pipeline of lead candidates targeting key neurodegenerative pathways. Its most advanced programs are in preclinical development, with plans to advance toward IND-enabling studies. AcuraStem’s platform has also attracted interest from academic and industry partners, providing non-dilutive funding and validation. With a strong scientific foundation and a clear focus on high-impact diseases, AcuraStem is positioned to become a leading player in neurodegenerative disease therapeutics. The company’s near-term value inflection points include nomination of development candidates and potential partnership announcements.

Upcoming Catalysts (preview)

• Q3 2026Nomination of lead clinical candidate for ALS program70% success
• Q4 2026Announcement of strategic partnership or licensing deal for FTD program50% success
• Q2 2026Presentation of preclinical data at major neurology conference90% success